keyword
MENU ▼
Read by QxMD icon Read
search

Locally advanced prostate cancer

keyword
https://www.readbyqxmd.com/read/29777523/application-of-cu-64-nodaga-psma-pet-in-prostate-cancer
#1
Sabina Sevcenco, Hans Christoph Klingler, Klaus Eredics, Alexander Friedl, Jenifer Schneeweiss, Peter Knoll, Thomas Kunit, Lukas Lusuardi, Siroos Mirzaei
INTRODUCTION: The high diagnostic potential of 64 Cu-PSMA PET-CT imaging was clinically investigated in prostate cancer patients with recurrent disease and in the primary staging of selected patients with advanced local disease. The aim of our study is to assess the uptake behavior in the clinical setting of 64Copper Prostate-Specific Membrane Antigen (64 Cu PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) in prostate cancer. METHODS: A retrospective study was performed in 23 patients with intermediate, high risk and progressive disease at primary staging of prostate cancer...
May 17, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29775158/microrna-expression-in-tumour-tissue-and-plasma-in-patients-with-newly-diagnosed-metastatic-prostate-cancer
#2
Ahmed Hussein Zedan, Torben Frøstrup Hansen, Jannie Assenholt, Mindaugas Pleckaitis, Jonna Skov Madsen, Palle Jörn Sloth Osther
Prostate cancer is the most common cancer among men in the western world. Clinical practice is continuously challenged by the pitfalls of the available diagnostic tools. microRNAs may represent promising biomarkers in many types of human cancers, including prostate cancer. The aim of this study was to investigate microRNA expression in tumour tissue and matched plasma in a cohort of patients with primary metastatic prostate cancer. The relative expression of 12 microRNAs was assessed in diagnostic needle biopsies from the prostate and matched plasma samples in two prospective cohorts (screening cohorts) comprising 21 patients with metastatic prostate cancer and 25 control patients...
May 2018: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/29770311/-super-active-surveillance-mri-ultrasound-fusion-biopsy-and-ablation-for-less-invasive-management-of-prostate-cancer
#3
REVIEW
Jonathan B Bloom, Samuel A Gold, Graham R Hale, Kareem N Rayn, Vikram K Sabarwal, Ivane Bakhutashvili, Vladimir Valera, Baris Turkbey, Peter A Pinto, Bradford J Wood
Multiparametric magnetic resonance imaging (mpMRI) of the prostate has allowed clinicians to better visualize and target suspicious lesions during biopsy. Targeted prostate biopsies give a more accurate representation of the true cancer volume and stage so that appropriate treatment or active surveillance can be selected. Advances in technology have led to the development of MRI and ultrasound fusion platforms used for targeted biopsies, monitoring cancer progression, and more recently for the application of focal therapy...
April 2018: Gland Surgery
https://www.readbyqxmd.com/read/29770305/the-prostate-cancer-focal-therapy
#4
REVIEW
Filippo Pesapane, Francesca Patella, Enrico Maria Fumarola, Edoardo Zanchetta, Chiara Floridi, Gianpaolo Carrafiello, Chloë Standaert
Despite prostate cancer (PCa) is the leading form of non-cutaneous cancer in men, most patients with PCa die with disease rather than of the disease. Therefore, the risk of overtreatment should be considered by clinicians who have to distinguish between patients with high risk PCa (who would benefit from radical treatment) and patients who may be managed more conservatively, such as through active surveillance or emerging focal therapy (FT). The aim of FT is to eradicate clinically significant disease while protecting key genito-urinary structures and function from injury...
April 2018: Gland Surgery
https://www.readbyqxmd.com/read/29769196/an-in-vivo-screen-identifies-pygo2-as-a-driver-for-metastatic-prostate-cancer
#5
Xin Lu, Xiaolu Pan, Chang-Jiun Wu, Di Zhao, Shan Feng, Yong Zang, Rumi Lee, Sunada Khadka, Samirkumar B Amin, Eun-Jung Jin, Xiaoying Shang, Pingna Deng, Yanting Luo, William R Morgenlander, Jacqueline Weinrich, Xuemin Lu, Shan Jiang, Qing Chang, Nora M Navone, Patricia Troncoso, Ronald A DePinho, Y Alan Wang
Advanced prostate cancer displays conspicuous chromosomal instability and rampant copy number aberrations, yet the identity of functional drivers resident in many amplicons remain elusive. Here, we implemented a functional genomics approach to identify new oncogenes involved in prostate cancer progression. Through integrated analyses of focal amplicons in large prostate cancer genomic and transcriptomic datasets as well as genes upregulated in metastasis, 276 putative oncogenes were enlisted into an in vivo gain-of-function tumorigenesis screen...
May 16, 2018: Cancer Research
https://www.readbyqxmd.com/read/29765147/systemic-treatments-for-high-risk-localized-prostate-cancer
#6
REVIEW
Géraldine Pignot, Denis Maillet, Emmanuel Gross, Philippe Barthelemy, Jean-Baptiste Beauval, Friederike Constans-Schlurmann, Yohann Loriot, Guillaume Ploussard, Paul Sargos, Marc-Olivier Timsit, Sébastien Vincendeau, Gilles Pasticier, Delphine Borchiellini
The majority of patients with prostate cancer who later develop lethal metastatic disease have high-risk localized disease at presentation, emphasizing the importance of effective treatment strategies at this stage. Multimodal treatment approaches that combine systemic and local therapies offer a promising strategy for improving the clinical outcomes of patients with high-risk localized prostate cancer. Combinations of neoadjuvant and adjuvant chemotherapy, hormonal therapy, or chemohormonal therapy are considered to be the standard of care in most solid tumours and should be investigated in the future for the treatment of prostate cancer to improve patient outcomes...
May 15, 2018: Nature Reviews. Urology
https://www.readbyqxmd.com/read/29764515/long-term-outcome-of-a-moderately-hypofractionated-intensity-modulated-radiotherapy-approach-using-an-endorectal-balloon-for-patients-with-localized-prostate-cancer
#7
Bin S Teh, Gary D Lewis, Weiyuan Mai, Ramiro Pino, Hiromichi Ishiyama, Edward Brian Butler
BACKGROUND: Technical advances in radiotherapy delivery have simultaneously enabled dose escalation and enhanced bladder and rectal sparing. However, the optimal radiation fractionation regimen for localized prostate cancer is unclear. Laboratory and clinical evidence suggest that hypofractionation may improve the therapeutic ratio of radiotherapy. We report our institutional outcomes using moderately hypofractionated, intensity-modulated radiotherapy (IMRT), and an endorectal balloon, with emphasis on long-term biochemical control and treatment-related adverse events in patients with localized prostate cancer...
April 17, 2018: Cancer communications
https://www.readbyqxmd.com/read/29755791/local-treatment-of-metastatic-prostate-cancer-what-is-the-evidence-so-far
#8
REVIEW
Pedro Leonel Almeida, Bruno Jorge Pereira
Background: Advances in technological, laboratorial, and imaging studies and new treatments available in the last decades significantly improved prostate cancer survival rates. However, this did not occur in metastatic prostate cancer (mPCa) at diagnosis which, in young and fit patients, will become invariably resistant to the established treatments. Progression will lead to an impairment in patients' quality of life and disease-related death. Methods: The authors intend to perform a literature review of the advantages of primary treatment of mPCa...
2018: Prostate Cancer
https://www.readbyqxmd.com/read/29755405/dual-paraneoplastic-endocrine-syndromes-heralding-onset-of-extrapulmonary-small-cell-carcinoma-a-case-report-and-narrative-review
#9
Jill B Feffer, Natalia M Branis, Jeanine B Albu
Objective: Extrapulmonary small cell carcinoma (EPSCC) is rare and frequent metastases at presentation can complicate efforts to identify a site of origin. In particular, SCC comprises <1% of prostate cancers and has been implicated in castration resistance. Methods: Clinical, laboratory, imaging, and pathology data are presented. Results: A 56-year-old man with locally advanced prostate adenocarcinoma on androgen deprivation therapy presented with a clogged nephrostomy tube...
2018: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29752513/oligorecurrent-prostate-cancer-limited-to-lymph-nodes-getting-our-ducks-in-a-row-nodal-oligorecurrent-prostate-cancer
#10
Andrei Fodor, Andrea Lancia, Francesco Ceci, Maria Picchio, Morten Hoyer, Barbara Alicja Jereczek-Fossa, Piet Ost, Paolo Castellucci, Elena Incerti, Nadia Di Muzio, Gianluca Ingrosso
PURPOSE: Oligorecurrent prostate cancer with exclusive nodal involvement represents a common state of disease, amenable to local therapy. New radio-labeled tracers have enriched the possibility of cancer detection and treatment. In this review, we aim to illustrate the main nuclear medicine diagnostic options and the role of radiotherapy in this setting of patients. METHODS: We performed a PubMed search referring to the PRISMA guidelines to analyze the performance of PSMA- and choline-PET in detecting oligorecurrence limited to lymph nodes, and to review the main studies supporting either ablative stereotactic body radiotherapy or regional lymph node irradiation in this clinical setting...
May 11, 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29745478/laparoscopic-abdominoperineal-resection-with-lateral-lymph-node-dissection-for-advanced-rectal-and-prostate-cancer-with-synchronous-lateral-lymph-node-metastases
#11
Takahisa Ishikawa, Shigenori Homma, Makoto Nishikawa, Hiroki Nakamoto, Ryoji Yokoyama, Akinobu Taketomi
Here we report a case of advanced rectal and prostate cancer with synchronous lateral lymph node (LLN) metastases that was treated with laparoscopic surgery. A 71-year-old man presented with fecal occult blood and was diagnosed with rectal cancer. A metastatic right LLN was suspected after CT examination of a 19-mm lymph node (proximal internal iliac artery region) and a 13-mm lymph node (distal internal iliac artery region) in the right lateral region. We planned neoadjuvant chemotherapy to suppress local and distant recurrence...
May 10, 2018: Asian Journal of Endoscopic Surgery
https://www.readbyqxmd.com/read/29744674/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-women-with-estrogen-receptor-positive-or-triple-negative-breast-cancer
#12
Aditya Bardia, Ayca Gucalp, Noashir DaCosta, Nashat Gabrail, Michael Danso, Haythem Ali, Kimberly L Blackwell, Lisa A Carey, Joel R Eisner, Edwina S Baskin-Bey, Tiffany A Traina
PURPOSE: Seviteronel (INO-464) is an oral, selective cytochrome P450c17a (CYP17) 17,20-lyase (lyase) and androgen receptor inhibitor with in vitro and in vivo anti-tumor activity. This open-label phase 1 clinical study evaluated safety, tolerability, pharmacokinetics (PK), and activity of once-daily (QD) seviteronel in women with locally advanced or metastatic TNBC or ER+ breast cancer. METHODS: Seviteronel was administered in de-escalating 750, 600, and 450 mg QD 6-subject cohorts...
May 9, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29741977/laparoscopic-pelvic-exenteration-for-locally-advanced-rectal-cancer-technique-and-short-term-outcomes
#13
Ashish Pokharkar, Praveen Kammar, Ashwin D'souza, Rahul Bhamre, Pavan Sugoor, Avanish Saklani
BACKGROUND: Since last two decades minimally invasive techniques have revolutionized surgical field. In 2003 Pomel first described laparoscopic pelvic exenteration, since then very few reports have described minimally invasive approaches for total pelvic exenteration. METHODS: We report the 10 cases of locally advanced rectal adenocarcinoma which were operated between the periods from March 1, 2017 to November 11, 2017 at the Tata Memorial Hospital, Mumbai. All male patients had lower rectal cancer with prostate involvement on magnetic resonance imaging (MRI)...
May 9, 2018: Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A
https://www.readbyqxmd.com/read/29736376/a-rare-case-of-isolated-castrate-resistant-bilateral-testicular-metastases-in-advanced-prostate-cancer
#14
Jiarui Su, Edwin Jonathan Aslim, Hakan Aydin, Puay Hoon Tan, Henry Sun Sien Ho
Testicular metastasis is rare with the prostate being the most common site of primary cancer. We report a case of a 72-year-old man with castration-resistant prostate cancer (CRPC) and known metastases to bone and lymph nodes, who developed bilateral painful swollen testes 3 years after the initial diagnosis of prostate cancer. He had first presented with lower urinary tract symptoms (LUTS) with suspicious findings on digital rectal examination of the prostate, and an elevated serum prostate specific antigen (PSA) level of 129 ng/mL...
April 2018: Asian Journal of Urology
https://www.readbyqxmd.com/read/29735545/nuclear-igf-1r-interacts-with-regulatory-regions-of-chromatin-to-promote-rna-polymerase-ii-recruitment-and-gene-expression-associated-with-advanced-tumor-stage
#15
Tamara Aleksic, Nicki E Gray, Xiaoning Wu, Guillaume Rieunier, Eliot Osher, Jack Mills, Clare Verrill, Richard J Bryant, Cheng Han, Kathryn Hutchinson, Adam Lambert, Rajeev Kumar, Freddie C Hamdy, Ulrike Weyer-Czernilofsky, Michael Sanderson, Thomas Bogenrieder, Stephen Taylor, Valentine M Macaulay
Internalization of ligand-activated type 1 IGF receptor (IGF-1R) is followed by recycling to the plasma membrane, degradation or nuclear translocation. Nuclear IGF-1R reportedly associates with clinical response to IGF-1R inhibitory drugs, yet its role in the nucleus is poorly characterized. Here we investigated the significance of nuclear IGF-1R in clinical cancers and cell line models. In prostate cancers, IGF-1R was predominantly membrane-localized in benign glands, while malignant epithelium contained prominent internalized (nuclear/cytoplasmic) IGF-1R, and nuclear IGF-1R associated significantly with advanced tumor stage...
May 7, 2018: Cancer Research
https://www.readbyqxmd.com/read/29734647/recent-advances-in-prostate-cancer-treatment-and-drug-discovery
#16
REVIEW
Ekaterina Nevedomskaya, Simon J Baumgart, Bernard Haendler
Novel drugs, drug sequences and combinations have improved the outcome of prostate cancer in recent years. The latest approvals include abiraterone acetate, enzalutamide and apalutamide which target androgen receptor (AR) signaling, radium-223 dichloride for reduction of bone metastases, sipuleucel-T immunotherapy and taxane-based chemotherapy. Adding abiraterone acetate to androgen deprivation therapy (ADT) in order to achieve complete androgen blockade has proven highly beneficial for treatment of locally advanced prostate cancer and metastatic hormone-sensitive prostate cancer (mHSPC)...
May 4, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29730201/androgen-receptor-targeted-treatments-for-prostate-cancer-35-years-progress-with-antiandrogens
#17
REVIEW
E David Crawford, Paul F Schellhammer, David G McLeod, Judd W Moul, Celestia S Higano, Neal Shore, Louis Denis, Peter Iversen, Mario A Eisenberger, Fernand Labrie
PURPOSE: Antiandrogens inhibit the androgen receptor (AR) and play an important role in the treatment of prostate cancer (PC). This review provides a historical perspective on the development and clinical benefit of antiandrogens in the treatment of PC. MATERIALS AND METHODS: We searched PubMed® for clinical trials with the search terms "antiandrogens" and "prostate cancer" combined with drug names for antiandrogens. This article represents a collaboration of clinical investigators who have made critical scientific contributions leading to the approval of antiandrogens for treating patients with PC...
May 3, 2018: Journal of Urology
https://www.readbyqxmd.com/read/29717358/survival-after-radical-prostatectomy-or-radiotherapy-for-locally-advanced-ct3-prostate-cancer
#18
Marco Bandini, Michele Marchioni, Felix Preisser, Emanuele Zaffuto, Zhe Tian, Derya Tilki, Francesco Montorsi, Shahrokh F Shariat, Fred Saad, Alberto Briganti, Pierre I Karakiewicz
PURPOSE: No prospective data examined the effect of radical prostatectomy (RP) vs. external beam radiotherapy (EBRT) in locally advanced prostate cancer (PCa). We aimed to compare survival outcomes of RP and EBRT in patients harboring cT3N0-1 PCa. METHODS: Within the SEER database (2004-2014), we identified 5500 cT3N0-1 PCa patients. Cumulative incidence plots and competing-risks regression models (CRRs) tested cancer-specific mortality (CSM) and other cause of mortality (OCM) according to treatment type...
May 2, 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29717261/antagonizing-cd105-enhances-radiation-sensitivity-in-prostate-cancer
#19
Anisha Madhav, Allen Andres, Frank Duong, Rajeev Mishra, Subhash Haldar, Zhenqiu Liu, Bryan Angara, Roberta Gottlieb, Zachary S Zumsteg, Neil A Bhowmick
Radiation therapy is the primary intervention for nearly half of the patients with localized advanced prostate cancer and standard of care for recurrent disease following surgery. The development of radiation-resistant disease is an obstacle for nearly 30-50% of patients undergoing radiotherapy. A better understanding of mechanisms that lead to radiation resistance could aid in the development of sensitizing agents to improve outcome. Here we identified a radiation-resistance pathway mediated by CD105, downstream of BMP and TGF-β signaling...
May 2, 2018: Oncogene
https://www.readbyqxmd.com/read/29715154/radiotherapy-plus-total-androgen-block-versus-radiotherapy-plus-lhrh-analog-monotherapy-for-non-metastatic-prostate-cancer
#20
Giulia Marvaso, Anna Viola, Cristiana Fodor, Barbara A Jereczek-Fossa
BACKGROUND/AIM: Patients with locally advanced prostate cancer are generally treated with radiotherapy (RT) which can be combined with hormonal therapy. RT plus monotherapy with luteinizing hormone-releasing hormone (LHRH) analog triptorelin was compared to RT plus total androgen block (TAB). PATIENTS AND METHODS: A retrospective study was carried out on patients with locally advanced prostate cancer comparing RT plus monotherapy versus RT plus TAB. RESULTS: For overall survival, no differences between patients receiving RT with monotherapy and those treated with TAB were observed...
May 2018: Anticancer Research
keyword
keyword
3465
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"